To further explore the response of MCM10 to cancer immunotherapy, we analyzed the immunotherapy cohort data IMvigor210 and showed that high MCM10 expression was more efficacious for PD-L1 treatment (Figure S11F). This evidence concerns the gene CD274 and cancer.